NUCLEAR MEDICINE AND BIOLOGY

Nuclear Medicine and Biology publishes original research addressing all aspects of radiopharmaceutical science: synthesis| in vitro and ex vivo studies| in vivo biodistribution by dissection or imaging| radiopharmacology| radiopharmacy| and translational clinical studies of new targeted radiotracers. The importance of the target to an unmet clinical need should be the first consideration. If the synthesis of a new radiopharmaceutical is submitted without in vitro or in vivo data| then the uniqueness of the chemistry must be emphasized. These multidisciplinary studies should validate the mechanism of localization whether the probe is based on binding to a receptor| enzyme| tumor antigen| or another well-defined target. The studies should be aimed at evaluating how the chemical and radiopharmaceutical properties affect pharmacokinetics| pharmacodynamics| or therapeutic efficacy. Ideally| the study would address the sensitivity of the probe to changes in disease or treatment| although studies validating mechanism alone are acceptable. Radiopharmacy practice| addressing the issues of preparation| automation| quality control| dispensing| and regulations applicable to qualification and administration of radiopharmaceuticals to humans| is an important aspect of the developmental process| but only if the study has a significant impact on the field. Contributions on the subject of therapeutic radiopharmaceuticals also are appropriate provided that the specificity of labeled compound localization and therapeutic effect have been addressed.

数据整理自公开网络的投稿反馈，仅供参考。